HOME
Home
OUR TEAM
Nav
SCIENCE&PIPELINE
Nav
NEWS
Nav
CONTACT
Nav
ACADEMICIAN WORKSTATION
LEADING SCIENTISTS
CORE TEAM
COLLABORATING SCIENTISTS AND ORGANIZATION
OUR FOCUS
PIPELINE
IN-DEPTH LOOK
SCIENTIFIC PUBLICATION
PRESS RELEASE
MEDIA REPORT
Article list
Aomo Announces China's NMPA Acceptance of NDA for Adamgammadex
2024-09-19
Introduction of neuromuscular blocking agents
2024-07-26
Cisatracurium
2024-08-06
Unmet clinical needs in reversal of neuromuscular blocking agents
2024-07-31
Combined Rocuronium and Cisatracurium in Surgical Procedures
2024-09-27
Recurarization after Reversal of NMB with Sugammadex
2024-09-27
Propofol
2024-09-27
Dry eye disease
2024-09-27
Anaphylaxis in Perioperative Anaesthesia
2024-08-27
Sugammadex is a significant milestone in the development of anesthesia
2024-07-31
Record-breaking China’s Pharmaceutical Innovations Present at the AACR Annual Meeting
2024-04-19
Encouraging Phase III Clinical Data of Adamgammadex Presented at the 2024 WCA
2024-03-07
Aom0315 Completes the Enrollment and Safety Follow-Up of All Subjects for Phase I Clinical Trials
2024-02-18
Shanghai Argo Entered into Collaboration Agreements on Multi-Program RNAi Licenses with Novartis
2024-01-15
MediLink Therapeutics Entered into Worldwide Collaboration and License Agreement with Roche.
2024-01-15
Amogammadex Was Designated as INN for Adamgammadex (Aom0498) by WHO.
2024-01-12
AMCKAUS Pharm Completed Dosing of SAD in Phase I Clinical Trial of Aom0315 in Australia
2024-01-12
British Journal of Anaesthesia Published the Phase III Clinical Results of Adamgammadex.
2024-01-12
Prev
1
Next
Our Team
Science & pipeline
News
Contact
US Address: 1608 E AYRE NEWPORT DE 19804, USA Australia Address: 7 DERHAM ST SPOTSWOOD VIC 3015
Contact 1: 1-347-766-6808 Contact 2: 512-831-8217
E-mail:alobal@adammerck.cor
Academician Workstation
Leading Scientist
s
Core Team
Collaborating Scientists and Organizations
Our Focus
Product Pipeline
In-depth L
ook
Scientific Publication
Press Release
Contact
Media Report